Research-use agreement required
You must actively agree before entering Revalin.
All products are strictly for research purposes only and are not intended for human consumption. These products have not been evaluated or approved by the FDA or Health Canada.
You must be 21 or older to browse this site.
Optional research details
Leaving these fields blank records that no institution or research details were provided.
This is the research-use access gate, separate from cookie consent.
By clicking Yes, you confirm you are 21 or older, are acting for lawful research purposes, and agree to our Terms of Service and Privacy Policy.
Research library
Papers & protocols, as published.
Curated research chemical literature from the Revalin team. All content is intended for licensed researchers working in laboratory settings.
Women's Health
GHK-CU for Women: Research, Benefits & Evidence
GHK-CU is an endogenous copper-binding tripeptide that declines 60% between young adulthood and age 60 — precisely when the female body becomes most vulnerable to estrogen-driven collagen loss, follicle miniaturization, and neuroinflammation. This synthesis of 2020–2026 literature maps the compound's multi-system biology to the female lifespan, from wound healing in the 20s through neuroprotection in the post-menopausal decades
Women's Health
Retatrutide and Women's Health: The Definitive 2026 Research Review
The GLP-3 triple agonist is rewriting the rules of obesity medicine — and for women, the implications go far beyond the scale. This research review covers Phase 3 trial data showing 28.7% average weight loss, groundbreaking cancer findings in triple-negative breast cancer and pancreatic tumors, hormonal restoration in PCOS, 90% liver fat normalization in MASH, and cardiovascular breakthroughs — all sourced from NEJM, The Lancet, Nature Medicine, and the full TRIUMPH clinical program.